The wettability of pharmaceuticals is a key physical property which influences their dissolution rate, dispersibility, flowability and solid-state stability. Here, we provide a platform of surface nanoengineering methods capable of tuning the wettability of drug powders from high hydrophilicity to superhydrophobicity with drug loadings up to 95–99%. Specifically, we functionalize gram-scale micronized budesonide, a commercial active pharmaceutical ingredient for respiratory diseases, in a vibrated fluidized bed reactor with inorganic Al₂O₃, TiO₂ and SiO₂ by atomic layer deposition (ALD), organic poly(ethylene terephthalate) (PET) by molecular layer deposition (MLD) and inorganic/organic titanicone by hybrid ALD/MLD. Transmission electron microscopy shows the formation of smooth and uniform films for each deposition process without significantly affecting the surface morphology of the budesonide particles. Crucially, the deposition processes do not alter the solid-state structure and cytocompatibility of budesonide. The ceramic ALD films are able to convert the originally hydrophobic budesonide into highly hydrophilic powders with water contact angles (WCAs) of ~10° within a few seconds. The purely organic PET films grown via MLD deliver superhydrophobic powders with a WCA of 145–150°. In contrast, the titanicone hybrid ALD/MLD films lead to mild hydrophilicity with WCAs ranging from ~80° to ~60°. Modifying the wetting properties of inhaled drug powders such as budesonide is relevant to improve bioavailability, enhance the dispersion of formulations in suspension-based inhalers or prevent moisture interactions in dry powder inhalers. Moreover, by tuning the surface chemical composition at the atomic or molecular level, particle ALD, MLD and hybrid ALD/MLD enable control over powder wettability for several pharmaceutical dosage forms with applications in oral, orally inhaled and parenteral delivery.

@en

Fluidization of cohesive pharmaceutical powders is difficult to achieve and typically requires the introduction of external forces. This study investigates the fluidization of the fine inhalation grade of lactose powders (size range from 0.1-20 μm) that are specifically developed for dry powder inhalation (DPI) applications. The fluidization behaviour of fine lactose powders was evaluated under six conditions: without fluidization aids, with only vertical vibration (VFA), with only a downward-pointing micro-jet (MFA), with both vibration and pre-mixing with coarse particles (VCFA), with both vibration and micro-jet (VMFA), and with the combined assistance of vibration, micro-jet, and addition of coarse particles (VMCFA). The enhancement of fluidization due to the use of different assistance methods is reflected by the increase of bed expansion and the decrease in both the minimum fluidization velocity and agglomerate formation. However, applying micro-jet results in considerable powder losses due to the high fraction of fine particles stuck to the wall. Combining any two assisting methods leads to better fluidization than using a single approach. In particular, the combination of vibration and micro-jet shows the best performance in improving fluidization. Further addition of coarse particles does not play a significant influence on promoting fluidization. Finally, the analysis of the forces acting on the lactose agglomerates shows the enhancement of separation forces by introducing the fluidization assistance, which leads to a decrease in agglomerate size.@en

For dry powder inhaled formulations, good flow behaviour is vital in re-dispersing the powder. However, inhaled drug powders with a particle size below 10 µm are classified as highly cohesive materials with poor flow characteristics. Here we demonstrate how to alter the flow properties of micronized budesonide powders by depositing different materials (organic, inorganic, and hybrid organic–inorganic) in the forms of nanoscale films onto the drug particles using atomic/molecular layer deposition (ALD/MLD) coatings. The angle of repose (static) and pneumatic delivery measurements were performed to access the flow characteristics. The flowability can be effectively improved with the growth of inorganic nanofilm (SiO₂, TiO₂, or Al₂O₃) via ALD and hybrid nanofilm (titanicone) via combined ALD-MLD coating. This improvement is reflected by the decrease in the angle of repose and minimum pick-up velocity (U_pu), as well as promoting the pneumatic delivery of a much larger amount of drug powders after ALD or hybrid coating. In contrast, the organic PET coated budesonide via MLD exhibits comparable poor flow characteristics as the uncoated budesonide. Rather than being transported in individual particles, the uncoated or PET-coated budesonide powders are pneumatically delivered in form of complex clusters with a size of over 500 μm, whereas the ALD budesonide is dispersed in form of small agglomerates (<100 μm). Despite the difference in agglomerate size, entraining behaviors of all samples agree well with the prediction of Kalman's pick-up Zone I correlation. The inorganic nanofilm deposited via ALD alters the surface chemistry to reduce the inter-particle forces measured by atomic force microscopy, giving rise to an improved drug delivery performance. Nanoscale surface modification of dry powder particles has good potential for inhaled drug delivery enhancement.

@en

Ideal controlled pulmonary drug delivery systems provide sustained release by retarding lung clearance mechanisms and efficient lung deposition to maintain therapeutic concentrations over prolonged time. Here, we use atomic layer deposition (ALD) to simultaneously tailor the release and aerosolization properties of inhaled drug particles without the need for lactose carrier. In particular, we deposit uniform nanoscale oxide ceramic films, such as Al2O3, TiO2, and SiO2, on micronized budesonide particles, a common active pharmaceutical ingredient for the treatment of respiratory diseases. In vitro dissolution and ex vivo isolated perfused rat lung tests demonstrate dramatically slowed release with increasing nanofilm thickness, regardless of the nature of the material. Ex situ transmission electron microscopy at various stages during dissolution unravels mostly intact nanofilms, suggesting that the release mechanism mainly involves the transport of dissolution media through the ALD films. Furthermore, in vitro aerosolization testing by fast screening impactor shows a μ2-fold increase in fine particle fraction (FPF) for each ALD-coated budesonide formulation after 10 ALD process cycles, also applying very low patient inspiratory pressures. The higher FPFs after the ALD process are attributed to the reduction in the interparticle force arising from the ceramic surfaces, as evidenced by atomic force microscopy measurements. Finally, cell viability, cytokine release, and tissue morphology analyses verify a safe and efficacious use of ALD-coated budesonide particles at the cellular level. Therefore, surface nanoengineering by ALD is highly promising in providing the next generation of inhaled formulations with tailored characteristics of drug release and lung deposition, thereby enhancing controlled pulmonary delivery opportunities.

@en